

#### Validation Of The Integrated Medical Model Using Historical Space Flight Data

Eric Kerstman M.D., M.P.H.

**Advanced Projects** 

Wyle Integrated Science and Engineering Group

2010 Winter Simulation Conference Baltimore, MD December 7, 2010



#### Validation of the Integrated Medical Model Using Historical Space Flight Data

Eric L. Kerstman<sup>1</sup>, Charles Minard<sup>2</sup>, Mary H. Freire de Carvalho<sup>2</sup>, Marlei E. Walton<sup>2</sup>, Jerry G. Myers. Jr.<sup>3</sup>, Lynn G. Saile<sup>2</sup>, Vilma Lopez<sup>4</sup>, Douglas J. Butler<sup>2</sup>, Kathy A. Johnson-Throop<sup>5</sup>

<sup>1</sup>University of Texas Medical Branch, Galveston, TX; <sup>2</sup>Wyle, Houston, TX, <sup>3</sup>NASA Glenn Research Center, Cleveland, OH, <sup>4</sup>JesTech, Houston, TX, <sup>5</sup>NASA Johnson Space Center, Houston, TX

# Background



- The IMM is expected to be a significant contributor to medical decision making in operational and planning processes for space flight missions
- NASA Standard 7009 requires that real world events be accurately represented by the model results to reach sufficient levels of validation
- For the IMM, this requirement is partially fulfilled by comparing the model's predicted outcomes with observed mission data that has not been included in the model

# Validation



- Model Validation
  - "Substantiation that a computerized model within its domain of applicability possesses a satisfactory range of accuracy consistent with the intended application of the model"
    - Schlesinger et al. Terminology for model credibility. Simulation. 32 (3): 103-104
- Historical Data Validation
  - "If historical data exist, part of the data is used to build the model and the remaining data are used to determine (test) whether the model behaves as the system does"
    - Sargent. Verification and Validation of Simulation Models. *Proceedings of the 2007 Winter Simulation Conference*

# Data Analysis



- Data on historical space flight missions were collected from mission medical records
- Data available for comparison included
  - Total number of medical events
  - The number of occurrences of each medical event
  - Medical resource utilization

# **Validation Approach**



- Qualitative and quantitative approaches were used to compare historical data to model output
- Qualitative Approach
  - Plots were created to visualize the differences between the model and historical data
- Quantitative Approach
  - Goodness of Fit (GoF) testing was chosen to test the null hypothesis that the predicted outcomes are statistically equivalent to the observed data

# Methods



# **Data Collection**

- International Space Station (ISS) missions
  - Increment medical debriefs by ISS crew surgeons
  - ISS Private Medical Conference (PMC) Tool

### Space Shuttle Missions

- Mission medical debriefs by Shuttle crew surgeons
- Crew medical debriefs
- Surgeon logs

# Methods



# Simulation

- Model was run for seven ISS missions and fourteen Shuttle missions\*
- Mission and crew profile was matched to historical mission data [# of crew, sex, mission length, and number of extravehicular activities (EVAs)]
- Each simulation was executed for 20,000 trials
- \* Data from these missions have not been used as input for the model



# **Qualitative Approach**

- Spider Plots
  - Qualitatively assess the accuracy of IMM predictions for the total number of medical events
  - Simultaneously present the predicted and observed data for multiple missions
  - Primarily for face validation
  - Lacks formal statistical testing procedures
  - Useful in identifying potential discrepancies between the IMM and real-world events



# **Quantitative Approaches**

- Chi-squared Goodness of Fit (GoF)
  - May be utilized when the expected number of medical events is five or more (*e.g.* skin rashes, headaches)
  - Reasonable test for the total number of medical events, specific medical conditions that occur frequently, and medical resource utilization
  - The test statistic is calculated as:  $X_{ts}^2 =$

$$X_{ts}^{2} = \sum_{i=1}^{N} \frac{(E_{i} - O_{i})^{2}}{E_{i}} \sim X_{df, 1-\alpha}^{2}$$

- If the test statistic is greater than the critical value  $(X_{df,1-\alpha}^2)$ , then the null hypothesis that the predicted outcomes are statistically equivalent to observed data will be rejected
- An α = 0.05 level of significance was assumed for IMM GoF testing



# Quantitative Approaches (Cont'd)

- Exact Probability Calculations
  - When expected values for medical events are less than five, goodness of fit tests may be done using exact probability calculations
  - The p-value is equal to the proportion of simulated trials where the number of events that occurred is equal to or more than the observed number



- Multiple Comparisons
  - The alpha-level for statistical significance was determined using Bonferroni's correction method
  - If N statistical tests were performed and the overall alpha was set at 0.05, then the final alpha level for any individual test was 0.05/N
- Example
  - A single ISS mission with one crew member and 83 medical conditions
  - The alpha was 0.05/83 (0.0006)
  - Therefore, p-values less than or equal to 0.006 would be statistically significantly different



#### **Total Medical Events - ISS Missions**

Mission	Expected	Observed	Difference
1	12	7	5
2	18	14	4
3	18	13	5
4	14	10	4
5	15	14	1
6	17	16	1
7	19	23	-4
Average	16	14	2




#### **Total Medical Events**

- ISS Missions
  - Expected values overestimated the number of medical events for six of the seven missions
  - The difference was not statistically significant (p = 0.36)
  - The shape of the expected values is similar to the observed values



### Spider Plot for ISS Missions Total Number of Medical Events by Mission



#### **Results – Total Medical Events – Shuttle Missions**



Mission	# of Crew	Expected	Observed	Difference
1	6	24	26	-2
2	6	24	25	-1
3	6	24	22	2
4	7	28	27	1
5	6	25	31	-6
6	5	20	23	-3
7	6	26	28	-2
8	6	25	21	4
9	5	21	20	1
10	6	26	19	7
11	6	24	23	1
12	6	23	19	4
13	6	25	32	-8
14	6	24	21	3
Average	6	24	24	0

16




#### **Total Medical Events**

- Shuttle Missions
  - Expected values overestimated the number of medical events for eight missions
  - Expected values underestimated the number of medical events for six missions
  - The difference was not statistically different (p = 0.83)
  - The shape of the expected values is similar to the observed values



#### **Spider Plot for Shuttle Missions**

#### Total Number of Medical Events by Mission





- Specific Medical Events
  - 83 Medical conditions in the model
  - GoF testing performed for all conditions individually
  - Alpha level set at 0.0006 (0.05/83)



### **Specific Medical Events**

- ISS Missions
  - One medical condition was underestimated by the model (skin abrasion/laceration)
  - Three medical conditions were overestimated by the model (hip sprain/strain, paresthesias, and CO<sub>2</sub> headache)



### **Specific Medical Events**

- Shuttle Missions
  - Five medical conditions were underestimated by the model (nasal congestion, hip sprain/strain, constipation, early insomnia, and CO<sub>2</sub> headache)
  - One condition was overestimated by the model (space motion sickness)
  - Space adaptation headache and paresthesias were underestimated in some missions and overestimated in others



- Resource Utilization
  - Only available for Shuttle missions
  - Only pharmaceutical usage on Shuttle missions was reliably tracked
  - There are 204 resources in the model
  - The alpha level was set at 0.0002 (0.05/204)
  - Ten pharmaceutical resources were underestimated by the model
  - Eleven pharmaceutical resources were overestimated by the model



#### Pharmaceutical Resources Underestimated on one or more simulations

Resource	Overall p-value	
Afrin	0	
Ambien	0	
Double Antibiotic Ointment	0	
Dulcolax Suppository	0	
Sonata	0	
Bacitracin	1.51E-08	
Triamcinolone Cream	4.5E-08	
Aspirin	8.75E-07	
Dulcolax Tablet	7.8E-06	
Claritin	2.01E05	

### **Results – Resource Utilization**



#### Pharmaceutical Resources Overestimated on one or more simulations

Resource	Overall p-value		
Phenergan Tablet	1E-44		
Tylenol	5.69E-32		
Sudafed	7.43E-23		
Phenergan Injectable	4.76E-21		
Afrin	1.95E-17		
Ibuprofen	2.17E-13		
Milk of Magnesia	7.49E-07		
Ambien	7.49E-07		
Dulcolax Tablet	1.01E-05		
Benadryl Capsule	1.42E-05		
Povidone Iodine Swabs	1.71E-05		

# Discussion



- For both ISS and Shuttle missions, the total number of medical events expected was accurately predicted by the model
- For both ISS and Shuttle missions, specific medical events were forecast well by the model
- Shuttle medical resource utilization was well predicted by the model

# Limitations



- Limited number of ISS missions
- Missing or incomplete historical mission data
- Model baselined to ISS medical resources when analyzing Shuttle pharmaceutical utilization

# Conclusions



- This analysis provides strong evidence for the validity of the IMM in predicting medical event occurrences and resource utilization for ISS and Shuttle missions
- The model results were validated by historical mission data that have not been used in the model
- A small percentage of medical conditions and medical resource utilization were under or over predicted by the model
- These differences between model output and historical mission data can be used to improve model input data and the accuracy of predicted outcomes

# **Questions?**



